Supernus Pharma (SUPN) Posts Q2 Revenue Beat

Supernus Pharma (NASDAQ: SUPN) reported Q2 GAAP EPS of $0.14, which may not compare to the analyst estimate of $0.37. Revenue for the quarter came in at $170.1 million versus the consensus estimate of $165.94 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• FedEx (FDX) Tops Q4 EPS by 39c, Beats on Revenue; Offers FY27 EPS Guidance
• Cerebras Systems (CBRS) Misses Q1 EPS, Revenues Beat